We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inovio (INO) Veterinary Vaccine Rights Licensed to Plumbline
Read MoreHide Full Article
Inovio Pharmaceuticals, Inc. (INO - Free Report) announced that it has licensed a veterinary vaccine for the treatment of foot and mouth disease (FMD) to a South Korean animal health company, Plumbline Life Sciences.
Inovio will get milestone payments as well as royalties from Plumbline on product sales of the FMD synthetic vaccine in Asia, excluding Japan. Plumbline will also fund all development activities related to the vaccine.
Per Inovio’s press release, FMD is one of the most infectious diseases affecting farm animals including cattle, swine, sheep and goats, and is therefore a serious threat to global food safety. Considering that the disease can spread rapidly and beyond regional boundaries, there is urgent need to develop vaccines that can simultaneously target different regional serotypes of FMD in a single vaccine.
Inovio’s FMD DNA vaccine has demonstrated potential to prevent the virus from infecting livestock animals in previous studies and thus may be a global solution. Moreover, Inovio's SynCon technology will allow rapid development of vaccines that can cover multiple serotypes simultaneously with a single formulation.
We note that this is Inovio’s second license agreement with Plumbline for the development of animal health products and market opportunities. In 2014, Inovio had sold other animal health assets to Plumbline for cash and a significant equity position in the company.
We are positive on the latest development. It will not only help Inovio monetize non-core assets but will also allow the company to focus on human immunotherapies to help fight cancers and infectious diseases.
Inovio currently has a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector include Geron Corporation (GERN - Free Report) , Anika Therapeutics Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Inovio (INO) Veterinary Vaccine Rights Licensed to Plumbline
INOVIO PHARMAC Price
INOVIO PHARMAC Price | INOVIO PHARMAC Quote
We note that this is Inovio’s second license agreement with Plumbline for the development of animal health products and market opportunities. In 2014, Inovio had sold other animal health assets to Plumbline for cash and a significant equity position in the company.
We are positive on the latest development. It will not only help Inovio monetize non-core assets but will also allow the company to focus on human immunotherapies to help fight cancers and infectious diseases.
Inovio currently has a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector include Geron Corporation (GERN - Free Report) , Anika Therapeutics Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . All three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>